October 2006 in “Urology” Finasteride may help treat BPH by affecting certain biological markers.
March 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
October 2025 in “Journal of the Endocrine Society” Finasteride lowers cholesterol but doesn't reduce heart-related events.
March 2023 in “The Journal of Urology” Men with better urinary symptoms have a lower risk of death.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
June 2026 in “Frontiers in Medicine” 5α-reductase inhibitors for hair loss can cause mild, reversible sexual side effects in some men.
1 citations
,
March 2021 in “F1000Research” Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
April 2022 in “Reactions Weekly” 6 citations
,
January 2003 in “PubMed” Finasteride reduces prostate size and symptoms with few side effects.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Cilostazol may help hair grow and could be a new treatment for hair loss.
August 2002 in “Inpharma Weekly”
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
April 2016 in “Journal of Investigative Dermatology” A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.
January 2009 in “Acta urologica Belgica” Finasteride effectively treats BPH by reducing prostate size and improving symptoms.
The combined treatment of Finasteride and Doxazosin affects prostate tissue by reducing cell growth and altering hormone levels.
20 citations
,
January 2004 in “PubMed” Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
29 citations
,
July 2012 in “The Journal of Sexual Medicine” Rats had lasting erectile problems after stopping a certain medication.
110 citations
,
October 2019 in “Translational Andrology and Urology” More men are getting benign prostatic hyperplasia, and there are many treatments, from medication to surgery, with new methods being developed.
5 citations
,
January 2001 in “Advances in protein chemistry” 5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.
34 citations
,
July 1993 in “PubMed” 6 citations
,
October 2024 in “Basic and Clinical Andrology” PRP injections are not proven effective for treating erectile dysfunction.
1 citations
,
May 2017 in “Urologe A” Using tamsulosin and finasteride together for benign prostatic syndrome has increased and shows improvement in symptoms, but more reliable comparisons are needed.
November 2023 in “The Journal of Urology” The conclusion is that future trials should report specific details about the PRP composition to better understand its effects on urologic conditions.
2 citations
,
May 2022 in “International Journal of Impotence Research” Finasteride may be linked to Peyronie’s disease, but more research is needed.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
January 2026 in “Pharmaceutical journal/The pharmaceutical journal” Finasteride and dutasteride now have stronger warnings for psychiatric and sexual side effects.
22 citations
,
September 2002 in “Der Urologe” Alpha1-blockers effectively improve urinary symptoms in BPH, with alfuzosin and tamsulosin having fewer side effects.
86 citations
,
July 1993 in “Drugs” Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.
46 citations
,
March 2001 in “Journal of endocrinological investigation” 5α-reductase inhibitors, like finasteride and dutasteride, effectively treat BPH, male baldness, and hirsutism, with potential for acne and prostate cancer prevention.